ArticlePLoS pathogens2016
Oral Tolerance to Environmental Mycobacteria Interferes with Intradermal, but Not Pulmonary, Immunization against Tuberculosis.
Article in PLoS pathogens, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 32 citations in OpenAlex.
- BCG and beyond: unlocking new frontiers in TB vaccine development.Frontiers in immunology · 2025Review
- Effects of non-tuberculous mycobacteria on BCG vaccine efficacy: A narrative review.Journal of clinical tuberculosis and other mycobacterial diseases · 2024Review
- Oral tolerance to systemic vaccination remains intact without RORγt expression in regulatory T cells.iScience · 2023Article
- Mucosal and systemic immune responses after a single intranasal dose of nanoparticle and spore-based subunit vaccines in mice with pre-existing lung mycobacterial immunity.Frontiers in immunology · 2023Article
- Early-life microbiota-immune homeostasis.Frontiers in immunology · 2023Review
- Mucosal exposure to non-tuberculous mycobacteria elicits B cell-mediated immunity against pulmonary tuberculosis.Cell reports · 2022Article
- Mucosal tissue regulatory T cells are integral in balancing immunity and tolerance at portals of antigen entry.Mucosal immunology · 2022Review
- CD4+CCR6+ T cells dominate the BCG-induced transcriptional signature.EBioMedicine · 2021Article
- Is mapping the BCG vaccine-induced immune responses the key to improving the efficacy against tuberculosis?Journal of internal medicine · 2020Review
- Lessons from Bacillus Calmette-Guérin: Harnessing Trained Immunity for Vaccine Development.Cells · 2020Review
- Design and Optimization of a Temperature-Stable Dry Powder BCG Vaccine.Pharmaceutical research · 2019Article
- Nontuberculous Mycobacteria and Heterologous Immunity to Tuberculosis.The Journal of infectious diseases · 2019Review
- Neonatal vaccine effectiveness and the role of adjuvants.Expert review of clinical immunology · 2019Review
- Respiratory Tract Deposition and Distribution Pattern of Microparticles in Mice Using Different Pulmonary Delivery Techniques.Vaccines · 2018Article
- Noninvasive vaccination against infectious diseases.Human vaccines & immunotherapeutics · 2018Review
- In Vivo Pulmonary Delivery and Magnetic-Targeting of Dry Powder Nano-in-Microparticles.Molecular pharmaceutics · 2017Article
- Bolstering Immunity through Pattern Recognition Receptors: A Unique Approach to Control Tuberculosis.Frontiers in immunology · 2017Review
- Immune Responses to Bacillus Calmette-Guérin Vaccination: Why Do They Fail to Protect againstFrontiers in immunology · 2017Review
- Tuberculosis Susceptibility and Vaccine Protection Are Independently Controlled by Host Genotype.mBio · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Bacille Calmette-Guérin (BCG) is currently the only approved vaccine against tuberculosis (TB) and is administered in over 150 countries worldwide. Despite its widespread use, the vaccine has a variable protective efficacy of 0-80%, with the lowest efficacy rates in tropical regions where TB is most prevalent. This variability is partially due to ubiquitous environmental mycobacteria (EM) found in soil and water sources, with high EM prevalence coinciding with areas of poor vaccine efficacy. In an effort to elucidate the mechanisms underlying EM interference with BCG vaccine efficacy, we exposed mice chronically to Mycobacterium avium (M. avium), a specific EM, by two different routes, the oral and intradermal route, to mimic human exposure. After intradermal BCG immunization in mice exposed to oral M. avium, we saw a significant decrease in the pro-inflammatory cytokine IFN-γ, and an increase in T regulatory cells and the immunosuppressive cytokine IL-10 compared to naïve BCG-vaccinated animals. To circumvent the immunosuppressive effect of oral M. avium exposure, we vaccinated mice by the pulmonary route with BCG. Inhaled BCG immunization rescued IFN-γ levels and increased CD4 and CD8 T cell recruitment into airways in M. avium-presensitized mice. In contrast, intradermal BCG vaccination was ineffective at T cell recruitment into the airway. Pulmonary BCG vaccination proved protective against Mtb infection regardless of previous oral M. avium exposure, compared to intradermal BCG immunization. In conclusion, our data indicate that vaccination against TB by the pulmonary route increases BCG vaccine efficacy by avoiding the immunosuppressive interference generated by chronic oral exposure to EM. This has implications in TB-burdened countries where drug resistance is on the rise and health care options are limited due to economic considerations. A successful vaccine against TB is necessary in these areas as it is both effective and economical.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.